Variation in induced CYP1A1 levels: Relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms

Pharmacogenetics

Volumn 10, Issue 1, 2000, Pages 11-24

  Smart, Joanne ^a   Daly, Ann K ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Ah receptor; CYP1A1; Genetic polymorphism; Induction

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; ETHOXYRESORUFIN DEETHYLASE; GLUTATHIONE TRANSFERASE;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CAUCASIAN; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; EXON; FEMALE; GENDER; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYMPHOCYTE; MALE; NEGRO; NORMAL HUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; RECEPTOR GENE; SEX DIFFERENCE; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; CELLS, CULTURED; CYTOCHROME P-450 CYP1A1; ENZYME INDUCTION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC SCREENING; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOBLOTTING; ISOENZYMES; LYMPHOCYTES; MALE; OXAZINES; POINT MUTATION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTORS, ARYL HYDROCARBON; REFERENCE VALUES; VARIATION (GENETICS);

EID: 0034054613     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200002000-00003     Document Type: Article

References (58)

1. Alexandrie A, Ingelman-Sundberg M, Seidegard J, Tornling G, Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study of host factors in relation to age at onset, gender and histologic cancer types. Carcinogenesis 1994; 15:1785-1790.
2. Bale AE, Nebert DW, McBride OW. Subchromosomal localization of the dioxin-inducible P1450 locus (CYP1) and description of two RFLPs detected with a 3*P1450 cDNA probe. Cytogenet Cell Genet 1987; 46:574-575.
3. Burke MD, Russell A, Prough A, Mayer RT. Characteristics of a microsomal cytochrome P-488-mediated reaction. Drug Metab Dispos 1977; 5:1-8.
4. Cascorbi I, Brockmöller J. Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996; 56:4965-4969.
5. Catteau A, Bechtel YC, Poisson N, Bechtel PR, Bonaiti-Pellie C. A population and family study of CYP1A2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995; 47:423-430.
6. Crofts F, Taioli E, Trachman J. Cosma GN, Currie D, Toniolo P, Garte SJ. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994; 15:2961-2963.
7. Daly AK, Steen VM, Fairbrother KS, Idle JR. CYP2D6 multi-allelism. Methods Enzymol 1996; 272:199-210.
8. Devito MJ, Beebe LE, Menache M, Birnbaum LS. Relationship between CYP1A enzyme activities and protein levels in rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Toxicol Environ Health 1996; 47:379-394.
9. Dolwick KM, Schmidt JV, Carver LA, Swanson HI, Bradfield CA. Cloning and expression of a human Ah receptor cDNA. Mol Pharmacol 1993; 44:911-917.
10. Fujii-Kuriyama Y, Imataka H, Sogawa K, Yasumoto K-I, Kikuchi Y.egulation of CYP1A1 expression. FASEB J 1992; 6:706-710.
11. Grove J, Brown ASM, Daly AK, Bassendine MF, James OFW, Day CP.he RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect of age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics 1998; 8:335-342.
12. Hakkola J, Pasanen M, Pelkonen O, Hukkanen J. Evisalmi S, Antilla S, et al. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis 1997; 18:391-397.
13. Hayashi K, Kukita Y, Inazuka M, Tahira T. Single-strand conformation polymorphism analysis. In: Cotton RGH, Edkins E, Forrest S, editors. Mutation detection: a practical approach. Oxford: IRL Press; 1998. pp. 7-24.
14. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991; 110:559-565.
15. Heuvel JPV, Clark GC, Thompson CL, McCoy Z, Miller CR, Lucier GW, Bell DA.YP1A1 mRNA levels as a human exposure biomarker: use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes. Carcinogenesis 1993; 14:2003-2006.
16. Hines RN, Matthis JM. Jacob CS. Identification of multiple regulatory elements on the human P450IA1 gene. Carcinogenesis 1988; 9:771-780.
17. Hirvonen A, Husgafvel-Pursianinen K, Karjalainen A, Antilla S, Vainio H.Point-mutational MSPI and IIe-Val polymorphisms closely linked in the CYP1A1 gene:lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prevent 1992; 1:485-489.
18. Jacquet M, Lambert V, Baudoux E, Muller M, Kremers P, Gielen J. Correlation between P450 CYP1A1 inducibility, MspI genotype and lung cancer incidence. Eur J Cancer 1996; 32A:1701-1706.
19. Jaiswal AK, Gonzalez FJ. Nebert DW. Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism. Nucl Acids Res 1985; 13:4503-4520.
20. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shonida N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Lett 1990; 263:131-133.
21. Kawajiri K, Watanabe J, Eguchi H, Nakachi K, Kiyohara C, Hayashi S. Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics 1995; 5:152-158.
22. Kellermann G, Luyten-Kellermann M, Shaw C. Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. Am J Hum Genet 1973a; 25:327-331.
23. Kellermann G, Shaw C, Luyten-Kellermann M. A Aryl hydrocarbon hydroxylase inducibility and broncogenic carcinoma. New Engl J Med 1973b; 289:934-937.
24. Ketterer B, Harris JM, Talaska G. The human glutathion S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect 1992; 98:87-94.
25. Kiyohara C, Hirohata C, Inutsuka S. The relationship between aryl-hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res 1996; 87:18-24.
26. Kiyohara C, Nakanashi Y, Inutsuka S, Takayama K, Hara N, Motohiro A, et al.he relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. Pharmacogenetics 1998; 8:315-324.
27. Kouri RE, McKinney CE, Slomiany DJ. Snodgrass DR, Wray NP, McLemore TL. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analysed in cryopreserved lymphocytes. Cancer Res 1982; 42:5030-5037.
28. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T7. Nature 1970; 227:680-685.
29. Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW, Garte SJ, et al.ssociation between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994; 4:242-246.
30. Leathart JBS. London SJ, Steward A, Adams JD, Idle JR, Daly AK. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 1998; 8:529-542.
31. London SJ, Daly AK, Fairbrolber KS, Holmes C, Carpenter CL, Navidi WC, Idle JR.ung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism. Cancer Res 1995; 55:6035-6067.
32. London SJ, Daly AK, Leathart JBS, Navidi WC, Carpenter CC, Idle JR. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles county. Carcinogenesis 1997; 18:1203-1214.
33. Micka J, Milatovich A, Menon A, Grabowski GA, Puga A, Nebert DW. Human Ah receptor (AHR) gene: localization to 7p1 5 and suggestive correlation of polymorphism with CYP1A1 inducibility. Pharmacogenetics 1997; 7:95-101.
34. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CTP1A2 gene. Cancer Epidemiol Biomarkers Prevent 1994; 3:413-421.
35. Nebert D, Gielen J. Genetic regulation of aryl hydrocarbon hydroxylase induction in the mouse. Fed Proc 1972; 31:1315-1325.
36. Nebert DW, Jones JE. Regulation of the mammalian cytochrome P1-450 (CYP1A1) gene. Int J Biochem 1989; 21:243-252.
37. Paigen B, Gurtoo H, Minowada J, Vincent R, Paigen K, Parier N, et al. Questionable relation of aryl hydrocarbon hydroxylase to lung cancer risk. New Engl J Med 1977; 297:346-350.
38. Paigen B, Ward E, Reilly A, Houten L, Gurtoo HL, Minowada JJ, et al. Seasonal variation of aryl hydrocarbon hydroxylase activity in human lymphocytes. Cancer Res 1981; 41:2757-2761.
39. Piechocki MP, Hines RN. Functional characterization of the human CYP1A1 negative response element: modulation of Ah receptor mediated transcriptional activity. Carcinogenesis 1998; 19:771-780.
40. Prasad R, Prasad N, Harrell JE. Thornby J. Liem JH, Hudgins PT, Tsuang J. Aryl hydrocarbon hydroxylase inducibility and lymphoblast formation in lung cancer patients. Int J Cancer 1979; 23:316-320.
41. Ravnik-Glavac M, Glavac D, Dean M. Sensitivity of single-strand conformation polymorphism and heteroduplex method for mutation detection in the cystic fibrosis gene. Hum Mol Genet 1994; 3:801-807.
42. Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione S-transferase active on trans-stilbene oxide are due to a gene deletion. Prof Natl Acad Sci USA 1988; 85:7293-7297.
43. Shields PG, Bowman ED, Harrington AM,Doan VT, Weston A. Polycyclic aromatic hydrocarbon-DNA adducts in human lung cancer susceptibility genes. Cancer Res 1993; 53: 3486-3492.
44. Shimada T, Yun C-H, Hiroshi Y, Gautier J-C, Beaune PH, Guengerich FP.haracterization of human lung microsomal cytochrome P-4501A1 and its role in the oxidation of chemical carcinogens. Mol Pharmacol 1992; 41:856-864.
45. Shimada T, Gillam EMJ, Suter T, Strickland PT, Guengerich FP, Yamaaki H. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos 1997; 29:617-622.
46. Shou M, Korzekwa KR, Crespi CL. Gonzalez FJ, Gelboin HV. The role of 12 cDNA-expressed human, rodent and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-diol. Mol Carcinogenesis 1994; 10:159-168.
47. Spurr NK, Gough AC, Stevenson K, Wolk CR. Msp-1 polymorphism detected with a cDNA probe for the P-450 I family on chromosome 15. Nucl Acids Res 1987; 15:5901.
48. Swanson H, Bradfield CA. The AH-receptor: genetics, structure and function. Pharmacogenetics 1993; 3:213-230.
49. Taioli E, Ford J, Trachman J. Li Y, Demopoulos R, Garte S. Lung cancer risk and CYP1A1 genotype in African Americans. Carcinogenesis 1998; 19:813-817.
50. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brogger A, Borresen A-L.uman CYP1A1 (cytochrome P1450) gene: lack of association between the MSp1 restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1991; 1:20-25.
51. Thompson CL, McCoy Z, Lambert JM, Andries MJ, Lucier GW. Relationships among benzo(a)pyrene metabolism, benzo(a)pyrene-diol-epoxide: DNA adduct formation, and sister chromatid exchanges in human lymphocytes from smokers and nonsmokers. Cancer Res 1989; 49:6503-6511.
52. Trell L, Korsgaard R. Janzon L, Trell E. Distribution and reproducibility of aryl hydrocarbon hydroxylase inducibilily in a prospective population study of middle-aged male smokers and nonsmokers. Cancer 1985; 56:1988-1994.
53. Vaury CT, Lainé R, Noguiez P, Coppet P, Jaulin C, Praz F, et al. Human glulathione S-transferase M1 null genotype is associated with a high inducibility of cytochrome P450 1A1 gene transcription. Cancer Res 1995; 55:5520-5523.
54. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism in man measured from metabolites of dietary caffeine. Carcinogenesis 1992; 13:1561-1568.
55. Wedlund PJ. Kimura S, Gonzalez F, Nebert D. 1462V mutation in the human CYP1A1 gene: lack of correlation with either the MspI 1.9 kb (M2) allele or CYP1A1 inducibility in a three generation family of east Mediterranean descent. Pharmacogenetics 1994; 4:21-26.
56. Whitlock JP. Mechanistic aspects of dioxin action. Chem Res Toxicol 1993; 6:754-763.
57. Zhang Z, Fasco MJ, Huang L, Guengerich F, Kaminsky L. Characterization of purified human recombinant cytochrome P450-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res 1996; 56:3929-3993.
58. Zhong S, Howie AF, Ketterer B, Taylor J, Hayes JD, Beckett GJ, et al. Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 1991; 12:1533-1537.